← Back to Clinical Trials
Recruiting NCT07243652

NCT07243652 I-DECIDE After Bronchiolitis Hospitalization

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07243652
Status Recruiting
Phase
Sponsor Seattle Children's Hospital
Condition Bronchiolitis Acute
Study Type INTERVENTIONAL
Enrollment 2,700 participants
Start Date 2025-11-01
Primary Completion 2029-05

Eligibility & Interventions

Sex All sexes
Min Age 0 Months
Max Age 24 Months
Study Type INTERVENTIONAL
Interventions
Moderate-Resource Implementation StrategyHigh-Resource Implementation Strategy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 2,700 participants in total. It began in 2025-11-01 with a primary completion date of 2029-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Although automatic follow-up is a nearly universal practice, research has shown that these visits are often unnecessary after hospitalizations caused by bronchiolitis. Despite endorsement by national pediatric authorities, robust evidence, and family enthusiasm for as-needed (PRN) follow-up, it remains substantially underutilized for children hospitalized for bronchiolitis. The goal of I-DECIDE is to compare the effects of two multi-component implementation strategies, both of which aim to (a) increase PRN follow-up prescribing by hospitalists (physicians who care for hospitalized children) and (b) decrease unnecessary follow-up visit attendance by families.

Eligibility Criteria

Inclusion Criteria: * Primary diagnosis of bronchiolitis, discharged by a generalist inpatient service from a non-ICU, non-emergency department, non-step down unit Exclusion Criteria: * Children with a history of gestational age \<28 weeks, chronic lung disease, complex or hemodynamically significant heart disease, immunodeficiency, or neuromuscular disease * Children being discharged with home oxygen therapy

Contact & Investigator

Central Contact

Eric Coon, MD, MS

✉ Eric.Coon@seattlechildrens.org

📞 206-884-1223

Frequently Asked Questions

Who can join the NCT07243652 clinical trial?

This trial is open to participants of all sexes, aged 0 Months or older, up to 24 Months, studying Bronchiolitis Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07243652 currently recruiting?

Yes, NCT07243652 is actively recruiting participants. Contact the research team at Eric.Coon@seattlechildrens.org for enrollment information.

Where is the NCT07243652 trial being conducted?

This trial is being conducted at Birmingham, United States, Glendale, United States, Phoenix, United States, Lodi, United States and 11 additional locations.

Who is sponsoring the NCT07243652 clinical trial?

NCT07243652 is sponsored by Seattle Children's Hospital. The trial plans to enroll 2,700 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology